每月抗血管内皮生长因子治疗增生型糖尿病视网膜病变可逆转视网膜血管渗漏和阻止进行性视网膜无灌注。
Reversal of Retinal Vascular Leakage and Arrest of Progressive Retinal Nonperfusion With Monthly Anti-Vascular Endothelial Growth Factor Therapy for Proliferative Diabetic Retinopathy.
机构信息
Department of Ophthalmology, Weill Cornell Medical College, New York, New York.
Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois.
出版信息
Retina. 2018 Sep;38(9):e74-e75. doi: 10.1097/IAE.0000000000002261.
Abstract
We report a case of proliferative diabetic retinopathy (PDR) with severe, vision-threatening retinal non-perfusion (RNP) in which anti-vascular endothelial growth factor (VEGF) therapy resulted not only PDR reversal but also in arrest of RNP and resolution of retinal vascular leakage which had previously preceded vascular dropout and progressive RNP in the same patient.
摘要
我们报告了一例增殖型糖尿病性视网膜病变（PDR）伴严重、威胁视力的视网膜无灌注（RNP），抗血管内皮生长因子（VEGF）治疗不仅逆转了 PDR，还阻止了 RNP 的进展，并解决了视网膜血管渗漏，此前该患者已经出现了血管闭塞和进行性 RNP。
相似文献
1
Reversal of Retinal Vascular Leakage and Arrest of Progressive Retinal Nonperfusion With Monthly Anti-Vascular Endothelial Growth Factor Therapy for Proliferative Diabetic Retinopathy.每月抗血管内皮生长因子治疗增生型糖尿病视网膜病变可逆转视网膜血管渗漏和阻止进行性视网膜无灌注。
Retina. 2018 Sep;38(9):e74-e75. doi: 10.1097/IAE.0000000000002261.
2
Evaluation of the New "SAVE" Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment.抗VEGF治疗过程中新型“SAVE”方案治疗糖尿病性黄斑水肿的评估
Curr Eye Res. 2016 Aug;41(8):1082-1086. doi: 10.3109/02713683.2015.1084641. Epub 2015 Nov 18.
3
Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.宽视野 OCT 血管造影和荧光素血管造影评估抗血管内皮生长因子治疗糖尿病视网膜病变和水肿的无灌注区。
Ophthalmology. 2019 Dec;126(12):1685-1694. doi: 10.1016/j.ophtha.2019.06.022. Epub 2019 Jun 26.
4
Impact of serous retinal detachment on the efficacy of ranibizumab in diabetic macular oedema.浆液性视网膜脱离对雷珠单抗治疗糖尿病性黄斑水肿疗效的影响。
Acta Ophthalmol. 2017 Aug;95(5):e434-e435. doi: 10.1111/aos.12973. Epub 2016 Jan 29.
5
IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.长期玻璃体内抗血管内皮生长因子治疗对糖尿病性黄斑水肿中预先存在的微观结构改变的影响。
Retina. 2018 Sep;38(9):1824-1829. doi: 10.1097/IAE.0000000000001788.
6
Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.糖尿病性黄斑水肿患者玻璃体内注射类固醇和抗血管内皮生长因子治疗后的视网膜炎症生物标志物成像
Acta Ophthalmol. 2017 Aug;95(5):464-471. doi: 10.1111/aos.13294. Epub 2016 Oct 24.
7
Foveal Microvascular Integrity Association With Anti-VEGF Treatment Response for Diabetic Macular Edema.黄斑中心凹微血管完整性与糖尿病性黄斑水肿抗VEGF治疗反应的相关性
Invest Ophthalmol Vis Sci. 2021 Jul 1;62(9):41. doi: 10.1167/iovs.62.9.41.
8
Full thickness macular hole following intravitreal ranibizumab injection for diabetic macular edema; a rare complication or coincidence?玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿后出现的全层黄斑裂孔：一种罕见的并发症还是巧合？
Indian J Ophthalmol. 2015 Apr;63(4):362-3. doi: 10.4103/0301-4738.158109.
9
Baseline Factors Associated with Diabetic Retinopathy Improvement in RIDE/RISE.RIDE/RISE研究中与糖尿病视网膜病变改善相关的基线因素。
Ophthalmol Retina. 2021 Jan;5(1):101-103. doi: 10.1016/j.oret.2020.07.016. Epub 2020 Jul 17.
10
Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema.玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿后的屈光变化。
Clin Exp Optom. 2018 May;101(3):397-399. doi: 10.1111/cxo.12637. Epub 2017 Nov 14.
引用本文的文献
1
Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and panretinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea.韩国增生型糖尿病视网膜病变患者抗血管内皮生长因子眼内注射与全视网膜光凝治疗的成本效益分析。
BMC Health Serv Res. 2023 Dec 11;23(1):1388. doi: 10.1186/s12913-023-10280-6.
2
The 2-Year Leakage Index and Quantitative Microaneurysm Results of the RECOVERY Study: Quantitative Ultra-Widefield Findings in Proliferative Diabetic Retinopathy Treated with Intravitreal Aflibercept.RECOVERY研究的2年渗漏指数和定量微动脉瘤结果：玻璃体内注射阿柏西普治疗增殖性糖尿病视网膜病变的定量超广角研究结果
J Pers Med. 2021 Nov 1;11(11):1126. doi: 10.3390/jpm11111126.
3
Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy.解析糖尿病视网膜病变中视网膜无灌注与抗血管内皮生长因子药物之间的关联。
Eye (Lond). 2022 Apr;36(4):692-703. doi: 10.1038/s41433-021-01750-4. Epub 2021 Aug 18.
本文引用的文献
1
Retinal reperfusion in diabetic retinopathy following treatment with anti-VEGF intravitreal injections.玻璃体内注射抗血管内皮生长因子治疗糖尿病视网膜病变后的视网膜再灌注
Clin Ophthalmol. 2017 Jan 21;11:193-200. doi: 10.2147/OPTH.S118807. eCollection 2017.
2
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内注射雷珠单抗治疗增殖性糖尿病视网膜病变的随机临床试验
JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217.
3
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.玻璃体内注射阿柏西普治疗糖尿病性黄斑水肿：VISTA 和 VIVID 研究的 100 周结果。
Ophthalmology. 2015 Oct;122(10):2044-52. doi: 10.1016/j.ophtha.2015.06.017. Epub 2015 Jul 18.
4
Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.血管内皮生长因子中和作用可延缓糖尿病黄斑水肿患者视网膜无灌注进展。
Ophthalmology. 2014 Sep;121(9):1783-9. doi: 10.1016/j.ophtha.2014.03.021. Epub 2014 Apr 24.
5
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.雷珠单抗治疗糖尿病性黄斑水肿：两项 III 期随机临床试验（RISE 和 RIDE）的结果。
Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11.
Zotero 插件